Key Study Results
Rheos® Pivotal Hypertension Trial
The effectiveness and safety of the Rheos System was evaluated in the Rheos Pivotal Trial. A total of 322 resistant hypertension patients participated in the trial. A subset of 60 patients from this trial had images of their heart taken prior to having the Rheos implant and after 12 months of therapy.
- 13% reduction of left ventricular mass
Pressure Volume Study
In a pressure volume study by Wachter R. et al, PV loop images were taken of a 78 year old male patient who had received 12 months of Barostim Therapy™ to evaluate the therapy’s impact on heart structure and function. The below PV loops demonstrate that Barostim Therapy significantly improves cardiac function by increasing the stroke volume and reducing the arterial resistance.
Barostim neo™ Heart Failure Study
11 patients with HFrEF enrolled in an open-label study of Barostim neo. Therapeutic effect was measured by chronic changes in NYHA functional class, Minnesota living with HF questionnaire, 6-minute walk distance, and estimated glomerular filtration rate (eGFR).
- Reduction in the pathologic elevation of sympathetic nerve activity present in HFrEF
- Improved 6-minute hall walk
- Improved NYHA class